PubRank

IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer (Neonab)

Clinical Trial ID NCT01830244

PubWeight™ 0.75‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01830244

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Molecular portraits of human breast tumours. Nature 2000 94.14
2 Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003 59.17
3 Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011 13.95
4 Triple-negative breast cancer. N Engl J Med 2010 11.39
5 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009 10.91
6 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005 9.70
7 Cells of origin in cancer. Nature 2011 6.85
8 The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003 6.57
9 Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011 6.11
10 CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011 4.54
11 Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006 3.52
12 The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009 3.25
13 Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010 2.94
14 The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 2008 2.28
15 Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009 2.23
16 NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008 2.18
17 Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 2010 2.16
18 MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005 2.06
19 Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res 2004 1.91
20 Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 2001 1.74
21 Stem cell quiescence. Clin Cancer Res 2011 1.69
22 Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ 2010 1.41
23 HDACi--targets beyond chromatin. Cancer Lett 2009 1.32
24 Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 2010 1.26
25 Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem 2003 1.24
26 CD44 expression and regulation during mammary gland development and function. J Cell Sci 2000 1.13
27 Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One 2011 1.05
28 The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep 2011 1.00
29 A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010 1.00
30 Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 2012 0.95
31 Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. Int J Cancer 2011 0.93
32 Functional magnetic resonance: biomarkers of response in breast cancer. Breast Cancer Res 2011 0.91
33 Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. Expert Rev Mol Med 2010 0.85
34 Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnol Annu Rev 2007 0.85
35 Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 2005 0.84
36 Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Res Treat 2011 0.83
37 A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Res Treat 2010 0.83
38 Aptamer-functionalized magnetic nanoparticle-based bioassay for the detection of ochratoxin A using upconversion nanoparticles as labels. Analyst 2011 0.82
39 Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. Br J Haematol 2011 0.82
40 Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation. Cancer Res 2011 0.81
41 Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67. Breast Cancer 2011 0.78
42 A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. Ann Oncol 2007 0.75
43 Neoadjuvant clinical trials for the treatment of primary breast cancer: the experience of the German study groups. Curr Oncol Rep 2012 0.75
44 Neoadjuvant nab-paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat 2016 0.75
Next 100